Skip to main content
Erschienen in: Neurological Sciences 10/2019

12.06.2019 | Original Article

Generation and validation of algorithms to identify subjects with dementia using administrative data

verfasst von: Jacopo C. DiFrancesco, Alessandra Pina, Giorgia Giussani, Laura Cortesi, Elisa Bianchi, Luca Cavalieri d’Oro, Emanuele Amodio, Alessandro Nobili, Lucio Tremolizzo, Valeria Isella, Ildebrando Appollonio, Carlo Ferrarese, Ettore Beghi

Erschienen in: Neurological Sciences | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To generate and validate algorithms for the identification of individuals with dementia in the community setting, by the interrogation of administrative records, an inexpensive and already available source of data.

Methods

We collected and anonymized information on demented individuals 65 years of age or older from ten general practitioners (GPs) in the district of Brianza (Northern Italy) and compared this with the administrative data of the local health protection agency (Agenzia per la Tutela della Salute). Indicators of the disease in the administrative database (diagnosis of dementia in the hospital discharge records; use of cholinesterase inhibitors/memantine; neuropsychological tests; brain CT/MRI; outpatient neurological visits) were used separately and in different combinations to generate algorithms for the detection of patients with dementia.

Results

When used individually, indicators of dementia showed good specificity, but low sensitivity. By their combination, we generated different algorithms: I-therapy with ChEI/memantine or diagnosis of dementia at discharge or neuropsychological tests (specificity 97.9%, sensitivity 52.5%); II-therapy with ChEI/memantine or diagnosis of dementia at discharge or neuropsychological tests or brain CT/MRI or neurological visit (sensitivity 90.8%, specificity 70.6%); III-therapy with ChEI/memantine or diagnosis of dementia at discharge or neuropsychological tests or brain CT/MRIMRI and neurological visit (specificity 89.3%, sensitivity 73.3%).

Conclusions

These results show that algorithms obtained from administrative data are not sufficiently accurate in classifying patients with dementia, whichever combination of variables is used for the identification of the disease. Studies in large patient cohorts are needed to develop further strategies for identifying patients with dementia in the community setting.
Literatur
1.
Zurück zum Zitat Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer’s disease. Lancet 388(10043):505–517CrossRefPubMed Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S et al (2016) Alzheimer’s disease. Lancet 388(10043):505–517CrossRefPubMed
2.
Zurück zum Zitat Mazzola P, Rimoldi SM, Rossi P, Noale M, Rea F, Facchini C et al (2016) Aging in Italy: the need for new welfare strategies in an old country. Gerontologist 56(3):383–390CrossRefPubMed Mazzola P, Rimoldi SM, Rossi P, Noale M, Rea F, Facchini C et al (2016) Aging in Italy: the need for new welfare strategies in an old country. Gerontologist 56(3):383–390CrossRefPubMed
3.
Zurück zum Zitat Collaborators GD (2018) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol Collaborators GD (2018) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol
4.
Zurück zum Zitat Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J et al (2013) Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 381(9882):2016–2023CrossRefPubMed Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J et al (2013) Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 381(9882):2016–2023CrossRefPubMed
5.
Zurück zum Zitat Fiest KM, Jetté N, Roberts JI, Maxwell CJ, Smith EE, Black SE et al (2016) The prevalence and incidence of dementia: a systematic review and meta-analysis. Can J Neurol Sci 43(Suppl 1):S3–S50CrossRefPubMed Fiest KM, Jetté N, Roberts JI, Maxwell CJ, Smith EE, Black SE et al (2016) The prevalence and incidence of dementia: a systematic review and meta-analysis. Can J Neurol Sci 43(Suppl 1):S3–S50CrossRefPubMed
6.
Zurück zum Zitat Weuve J, Barnes LL, Mendes de Leon CF, Rajan KB, Beck T, Aggarwal NT et al (2018) Cognitive aging in Black and White Americans: cognition, cognitive decline, and incidence of Alzheimer disease dementia. Epidemiology 29(1):151–159CrossRefPubMedPubMedCentral Weuve J, Barnes LL, Mendes de Leon CF, Rajan KB, Beck T, Aggarwal NT et al (2018) Cognitive aging in Black and White Americans: cognition, cognitive decline, and incidence of Alzheimer disease dementia. Epidemiology 29(1):151–159CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S (2017) CSF tau and the CSF tau/Abeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 3:CD010803PubMed Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S (2017) CSF tau and the CSF tau/Abeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 3:CD010803PubMed
9.
Zurück zum Zitat Hornberger J, Bae J, Watson I, Johnston J, Happich M (2017) Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer’s disease - the case of florbetapir. Curr Med Res Opin 33(4):675–685CrossRefPubMed Hornberger J, Bae J, Watson I, Johnston J, Happich M (2017) Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer’s disease - the case of florbetapir. Curr Med Res Opin 33(4):675–685CrossRefPubMed
10.
Zurück zum Zitat May BH, Feng M, Hyde AJ, Hügel H, Chang SY, Dong L et al (2018) Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: a systematic review and meta-analysis of cognitive outcomes. Int J Geriatr Psychiatry 33(3):449–458CrossRefPubMed May BH, Feng M, Hyde AJ, Hügel H, Chang SY, Dong L et al (2018) Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: a systematic review and meta-analysis of cognitive outcomes. Int J Geriatr Psychiatry 33(3):449–458CrossRefPubMed
11.
Zurück zum Zitat Anand A, Patience AA, Sharma N, Khurana N (2017) The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review. Eur J Pharmacol 815:364–375CrossRefPubMed Anand A, Patience AA, Sharma N, Khurana N (2017) The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review. Eur J Pharmacol 815:364–375CrossRefPubMed
12.
Zurück zum Zitat Riley GF (2009) Administrative and claims records as sources of health care cost data. Med Care 47(7 Suppl 1):S51–S55CrossRefPubMed Riley GF (2009) Administrative and claims records as sources of health care cost data. Med Care 47(7 Suppl 1):S51–S55CrossRefPubMed
13.
Zurück zum Zitat Willis AW (2015) Using administrative data to examine health disparities and outcomes in neurological diseases of the elderly. Curr Neurol Neurosci Rep 15(11):75CrossRefPubMed Willis AW (2015) Using administrative data to examine health disparities and outcomes in neurological diseases of the elderly. Curr Neurol Neurosci Rep 15(11):75CrossRefPubMed
14.
Zurück zum Zitat Kosteniuk JG, Morgan DG, O'Connell ME, Kirk A, Crossley M, Teare GF et al (2015) Incidence and prevalence of dementia in linked administrative health data in Saskatchewan, Canada: a retrospective cohort study. BMC Geriatr 15:73CrossRefPubMedPubMedCentral Kosteniuk JG, Morgan DG, O'Connell ME, Kirk A, Crossley M, Teare GF et al (2015) Incidence and prevalence of dementia in linked administrative health data in Saskatchewan, Canada: a retrospective cohort study. BMC Geriatr 15:73CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM (2017) Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimers Dement 13(1):28–37CrossRefPubMed Goodman RA, Lochner KA, Thambisetty M, Wingo TS, Posner SF, Ling SM (2017) Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimers Dement 13(1):28–37CrossRefPubMed
16.
Zurück zum Zitat Jaakkimainen RL, Bronskill SE, Tierney MC, Herrmann N, Green D, Young J et al (2016) Identification of physician-diagnosed Alzheimer’s disease and related dementias in population-based administrative data: a validation study using family physicians’ electronic medical records. J Alzheimers Dis 54(1):337–349CrossRefPubMed Jaakkimainen RL, Bronskill SE, Tierney MC, Herrmann N, Green D, Young J et al (2016) Identification of physician-diagnosed Alzheimer’s disease and related dementias in population-based administrative data: a validation study using family physicians’ electronic medical records. J Alzheimers Dis 54(1):337–349CrossRefPubMed
17.
Zurück zum Zitat Amra S, O'Horo JC, Singh TD, Wilson GA, Kashyap R, Petersen R et al (2017) Derivation and validation of the automated search algorithms to identify cognitive impairment and dementia in electronic health records. J Crit Care 37:202–205CrossRefPubMed Amra S, O'Horo JC, Singh TD, Wilson GA, Kashyap R, Petersen R et al (2017) Derivation and validation of the automated search algorithms to identify cognitive impairment and dementia in electronic health records. J Crit Care 37:202–205CrossRefPubMed
18.
Zurück zum Zitat Takada T, Fukuma S, Yamamoto Y, Tsugihashi Y, Nagano H, Hayashi M et al (2018) Development and validation of a prediction model for functional decline in older medical inpatients. Arch Gerontol Geriatr 77:184–188CrossRefPubMed Takada T, Fukuma S, Yamamoto Y, Tsugihashi Y, Nagano H, Hayashi M et al (2018) Development and validation of a prediction model for functional decline in older medical inpatients. Arch Gerontol Geriatr 77:184–188CrossRefPubMed
19.
Zurück zum Zitat Hoogerduijn JG, Buurman BM, Korevaar JC, Grobbee DE, de Rooij SE, Schuurmans MJ (2012) The prediction of functional decline in older hospitalised patients. Age Ageing 41(3):381–387CrossRefPubMed Hoogerduijn JG, Buurman BM, Korevaar JC, Grobbee DE, de Rooij SE, Schuurmans MJ (2012) The prediction of functional decline in older hospitalised patients. Age Ageing 41(3):381–387CrossRefPubMed
20.
Zurück zum Zitat Tay L, Lim WS, Chan M, Ali N, Mahanum S, Chew P et al (2015) New DSM-V neurocognitive disorders criteria and their impact on diagnostic classifications of mild cognitive impairment and dementia in a memory clinic setting. Am J Geriatr Psychiatry 23(8):768–779CrossRefPubMed Tay L, Lim WS, Chan M, Ali N, Mahanum S, Chew P et al (2015) New DSM-V neurocognitive disorders criteria and their impact on diagnostic classifications of mild cognitive impairment and dementia in a memory clinic setting. Am J Geriatr Psychiatry 23(8):768–779CrossRefPubMed
21.
Zurück zum Zitat American Medical Association Hospital (2005) International classification of diseases, 9th revision American Medical Association Hospital (2005) International classification of diseases, 9th revision
22.
Zurück zum Zitat Miller GC, Britt H (1995) A new drug classification for computer systems: the ATC extension code. Int J Biomed Comput 40(2):121–124CrossRefPubMed Miller GC, Britt H (1995) A new drug classification for computer systems: the ATC extension code. Int J Biomed Comput 40(2):121–124CrossRefPubMed
23.
Zurück zum Zitat François M, Sicsic J, Elbaz A, Pelletier Fleury N (2017) Trends in drug prescription rates for dementia: an observational population-based study in France, 2006–2014. Drugs Aging 34(9):711–721CrossRefPubMed François M, Sicsic J, Elbaz A, Pelletier Fleury N (2017) Trends in drug prescription rates for dementia: an observational population-based study in France, 2006–2014. Drugs Aging 34(9):711–721CrossRefPubMed
24.
Zurück zum Zitat Albrecht JS, Hanna M, Kim D, Perfetto EM (2018) Predicting diagnosis of Alzheimer’s disease and related dementias using administrative claims. J Manag Care Spec Pharm 24(11):1138–1145PubMed Albrecht JS, Hanna M, Kim D, Perfetto EM (2018) Predicting diagnosis of Alzheimer’s disease and related dementias using administrative claims. J Manag Care Spec Pharm 24(11):1138–1145PubMed
25.
Zurück zum Zitat Mar J, Arrospide A, Soto-Gordoa M, Machón M, Iruin Á, Martinez-Lage P et al (2018) Validity of a computerized population registry of dementia based on clinical databases. Neurologia Mar J, Arrospide A, Soto-Gordoa M, Machón M, Iruin Á, Martinez-Lage P et al (2018) Validity of a computerized population registry of dementia based on clinical databases. Neurologia
Metadaten
Titel
Generation and validation of algorithms to identify subjects with dementia using administrative data
verfasst von
Jacopo C. DiFrancesco
Alessandra Pina
Giorgia Giussani
Laura Cortesi
Elisa Bianchi
Luca Cavalieri d’Oro
Emanuele Amodio
Alessandro Nobili
Lucio Tremolizzo
Valeria Isella
Ildebrando Appollonio
Carlo Ferrarese
Ettore Beghi
Publikationsdatum
12.06.2019
Verlag
Springer International Publishing
Erschienen in
Neurological Sciences / Ausgabe 10/2019
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-019-03968-3

Weitere Artikel der Ausgabe 10/2019

Neurological Sciences 10/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.